Feb 14, 2018
Roivant expanding its horizon into metabolic diseases segment with USD 650 million diabetes pact with Poxel Roivant Sciences has recently signed a USD 650 million deal to acquire near-global rights to Poxel pharma’s phase 3-ready Type 2 diabetes drug (imeglimin). It’s been a while since Poxel was waiting f...
Read More...
Sep 15, 2017
Bayer and Berkeley Lights embark on a project to automate drug discovery Pharmaceutical giant Bayer and Berkeley Lights have announced their collaboration to conduct a strategic project on a discovery platform aimed to automate antibody discovery and development of cell lines. Bayer and Berkeley Lights’ platform- Be...
Read More...
A New Era for Multiple Myeloma Treatment: Bispecific Antibodies Enter the Fray
Jun 10, 2025
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
Newsletter/Whitepaper